$BKKT

Bakkt's Chief Commercial Officer, Daniel Ishag, discussed the complexities of building institutional-grade crypto infrastructure at a StoneX seminar, highlighting Bakkt's competitive advantage. Bakkt's technology and regulatory stack are highly regarded, with partners needing significant time and investment to replicate it. The company offers 24/7 stablecoin settlements and global licensing, positioning it as a key player in the crypto market. Bakkt's trading volume is currently at 0, but its fo

Bakkt Holdings (NYSE: BKKT) shares rose 15.47% to $8.66 on Friday, benefiting from a broader crypto market rally and positive regulatory developments. Bitcoin surged past $78,000, and the Treasury's debt repurchase program boosted risk-on sentiment. Bakkt's stock is highly volatile due to its smaller market cap and lower liquidity.

On Wednesday, notable insider trading activity occurred in U.S. stocks. Zentalis Pharmaceuticals (ZLAB) saw a major purchase by Walters Group, while Bakkt (BKKT), Universal Safety Products (UNSP), Advanced Flower Capital (AFCG), and Brilliant Earth (BID) also had significant insider buys. Astera Labs (ALAB), Adaptive Biotechnologies (ADPT), and PACS Group (PACS) reported insider sales, some mandatory for tax purposes. InvestingPro analysis suggests some stocks are undervalued or overvalued.

ALFRED MICHAEL purchased 296,567 indirectly-held shares of Bakkt, Inc. (BKKT) at $7.12 ($2.11M total) on 2026-08-18.

Bakkt appointed Alexander White as CFO as it pivots from crypto trading and loyalty to stablecoin infrastructure. The company sold loyalty and custody, expanded globally via MarushoHotta and a $9.4M investment in Transchem, and completed its April acquisition of Distributed Technologies Research. Bakkt cited “material progress” on its Aug. 10 earnings call.

Bakkt (BKKT) reported Q2 2026 revenue of $170.1 million, down 70% from $568.1 million, citing client transitions and weaker digital asset trading volumes. GAAP net income was $80.8 million, driven mainly by a $98.5 million non-cash gain from Transchem warrants. Total transacting volume was $168.8 million; management reiterated an EBITDA breakeven target in Q4 2026.

Bakkt, Inc. (BKKT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Bakkt Appoints Matt White as Chief Financial Officer for Next Phase of Global Growth ATLANTA, GA – August 17, 2026 – Bakkt, Inc. (NYSE: BKKT) (“Bakkt” or the “Company”) today announced the appointment of Matt White as Chief Financial Officer, effective August 17, 202

Bakkt Holdings, Inc. discussed its Q2 2026 operating framework and growth plans on an earnings call. Management reiterated a 2026 TTV target of about $2.5 billion and a year-end goal of 25,000 MAUs. It reported GAAP net income of $80.8 million, cash and restricted cash of $50.7 million, and SAV of $119 million as of June 30, 2026.

Bakkt’s CEO Akshay Naheta said the company expects adjusted EBITDA break-even in Q4 2026, without a specific date, citing execution and client activations. Management discussed take rates, cross-border margins, and reaffirmed a 2026 TTV target of about $2.5 billion. The firm outlined post-DTR acquisition progress and Bakkt Agent MAU target of ~25,000 by year-end 2026.

Bakkt, Inc. (BKKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bakkt Reports Second Quarter 2026 Results - GAAP net income of $80.8 million, or $1.96 per basic and $1.94 per diluted share - Six commercial offerings live across Bakkt Markets; Total Transacting Volume (“TTV”) of $168.8 million in Q2, including payments volume generated on acqu